Oric Pharmaceuticals Stock Quote ORIC - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

8.07

Bid

7.78

Ask

8.37

Volume

401,565

7.73 Day's Range 8.13

4.89 52 Week Range 16.65

Market Cap

543.723M

Previous Close

7.67

Open

7.73

Last Trade

8.25

Last Trade Time

Financial Volume

$ 3,198,802

VWAP

7.9658

Average Volume (3m)

580,697

Shares Outstanding

67,375,847

Dividend Yield

PE Ratio

-5.40

Earnings Per Share (EPS)

-1.49

Revenue

Net Profit

-100.7M

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company h... ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.oricpharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Oric Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ORIC. The last closing price for Oric Pharmaceuticals was $7.67. Over the last year, Oric Pharmaceuticals shares have traded in a share price range of $ 4.89 to $ 16.65.

Oric Pharmaceuticals currently has 67,375,847 shares outstanding. The market capitalization of Oric Pharmaceuticals is $543.72 million. Oric Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.40.

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an...

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.3	-13.8740661686	9.37	9.43	7.62	449383	8.47000888	CS
4	-5.64	-41.1378555799	13.71	13.89	7.62	486937	10.13143182	CS
12	-3.29	-28.9612676056	11.36	16.65	7.62	580697	12.54542137	CS
26	2	32.9489291598	6.07	16.65	5.85	492538	10.69789405	CS
52	3.05	60.7569721116	5.02	16.65	4.89	440771	9.06019868	CS
156	-15.05	-65.0951557093	23.12	26.7	2.36	389980	8.43672392	CS
260	-17.93	-68.9615384615	26	40.81	2.36	350343	12.00891977	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M